NorthSea Therapeutics Initiates Phase IIA Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

NorthSea Therapeutics B.V. announced the dosing of the first patient in its Phase IIa clinical trial of Orziloben in IFALD, an orphan liver disease affecting individuals on prolonged intravenous nutrition.